Company Profile

Stemline Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers. SL-401 consists of IL-3 recombinantly fused to a truncated diphtheria toxin payload. SL-701 is an immunotherapy designed to activate the immune system to attack tumors. SL-701 comprises various short synthetic peptides that correspond to epitopes of targets, including IL-13 receptor subunit alpha-2 (IL-13Ra2), ephrin type-A receptor 2 (EphA2) and survivin, present on brain cancer. SL-801 is an oral, small molecule that reversibly inhibits Exportin-1 (XPO1), also known as Chromosome Region Maintenance-1 (CRM-1), a nuclear transport protein.

Employees

Sector

Biotechnology & Medical Research

More about the company

06-14	Menarini Group and Stemline Therapeutics, Inc. Reports Data from the Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis	CI
05-28	The Menarini Group and Stemline Therapeutics, Inc. Presents New Data From The Phase 1b/2 ELEVATE Study Of Elacestrant In Combination With Capivasertib In Patients With ER+, HER2- Metastatic Breast Cancer	CI
05-25	Menarini Group Announces New Data At the American Society of Clinical Oncology 2026 Annual Meeting	CI
12-09	Menarini Group and Stemline Therapeutics, Inc. Presents Elacestrant Phase 2 Combination Data in Patients with ER+, HER2- Metastatic Breast Cancer at the 2025 San Antonio Breast Cancer Symposium	CI
11-24	Menarini Group and Stemline Therapeutics, Inc. to Present New Data Related to ELZONRIS	CI
20/03/25	Menarini Group and Stemline Therapeutics Inc. Announce Collaboration with VisualDx to Aid in Identifying People Who May Have Blastic Plasmacytoid Dendritic Cell Neoplasm	CI
12/12/24	Menarini Group Along with Stemline Therapeutics, Inc and Medsir Present the Phase III Study Adela	CI
11/12/23	Menarini Group Presents Initial Safety and Efficacy Data from Phase 1B/2 Elevate and Electra Combination Studies of Orserdu® (Elacestrant) in Patients with Er+, Her2- Metastatic Breast Cancer At the 2023 San Antonio Breast Cancer Symposium	CI
08/12/23	Menarini Group and Stemline Therapeutics, Inc. Presents New Progression-Free Survival Data from Emerald Clinical Study of Orserdu (Elacestrant) in Clinically Relevant Subgroups of Patients with Esr1 Mutations At Sabcs 2023	CI
21/11/23	The Menarini Group and Stemline Therapeutics, Inc. to Present New Data Related to ORSerDU	CI
31/10/23	Quantum Leap Healthcare Collaborative Initiates Landmark Phase 2 RECAST DCIS Platform Trial to Evaluate Alternative DCIS Treatments with Atossa Therapeutics, Havah Therapeutics, and the Menarini Group	CI
20/09/23	European Commission Approves Menarini Group?s ORSERDU (Elacestrant) for the Treatment of Patients with ER+, HER2- Locally Advanced or Metastatic Breast Cancer with an Activating ESR1 Mutation	CI
26/05/23	The Menarini Group and Stemline Therapeutics Announce Results from A New Analysis of the Pivotal EMERALD Clinical Study	CI

17/12/20	Stemline Therapeutics : The Menarini Group received the coveted XV Transatlantic Award from the American Chamber of Commerce in Italy	AQ
10/06/20	STEMLINE THERAPEUTICS INC : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
12/05/20	STEMLINE THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	AQ
05/05/20	Stemline Therapeutics : The Menarini Group signs the agreement for the acquisition of Stemline Therapeutics for a maximum consideration of $ 677 million	AQ
04/05/20	STEMLINE THERAPEUTICS INC : Entry into a Material Definitive Agreement, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)	AQ

16/01/19	Dow Jones Industrial Average : Les valeurs à suivre à Wall Street
16/01/19	USA-Les valeurs à suivre à Wall Street (actualisé)

Manager	Title	Age	Since
Ivan Bergstein CEO	Chief Executive Officer	60	-
David Gionco DFI	Director of Finance/CFO	65	16/01/2014
Jeffrey Levitt CMP	Compliance Officer	-	01/04/2021

Date	Insider	Type	Main position	Quantity	% Market Cap.
10/06/20	Kenneth Hoberman	Free	Chief Operating Officer	2,043,410	3.8914%
10/06/20	Daniel Hume	Tender	Director	35,468	0.0675%
10/06/20	David Gionco	Free	Chief Financial Officer	417,980	0.7960%

Stemline Therapeutics, Inc. Stock

Stocks

US85858C1071

Biotechnology & Medical Research

Latest news : Stemline Therapeutics, Inc.

Press Releases: Stemline Therapeutics, Inc.

News in other languages: Stemline Therapeutics, Inc.

Managers and Directors: Stemline Therapeutics, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
STEMLINE THERAPEUTICS, INC.	-.--%	-.--%	-	-	570M
ARGENX SE	+3.98%	+5.55%	+76.40%	+136.18%	56.21B
WUXI APPTEC CO., LTD.	-3.12%	+5.11%	+71.57%	+94.67%	55.38B
BIONTECH SE	+4.03%	+8.37%	-9.91%	-9.54%	23.75B
INSMED INCORPORATED	+2.94%	+5.03%	+11.70%	+428.82%	23.19B
WUXI BIOLOGICS (CAYMAN) INC.	+3.64%	+10.54%	+39.81%	-4.50%	18.14B
GENMAB A/S	+4.11%	+8.89%	+44.60%	-27.73%	16.84B
PHARMAESSENTIA CORPORATION	+2.57%	+20.26%	+181.98%	+355.99%	15.86B
EXELIXIS, INC.	+2.60%	+4.34%	+25.37%	+190.33%	13.56B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+7.20%	+10.70%	+42.91%	-	12.97B
Average	+2.80%	+7.25%	+53.83%	+145.53%	26.21B
Weighted average by Cap.	+2.20%	+6.09%	+57.45%	+135.89%